Propeller Health recently announced that its Propeller platform has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use with Breo Ellipta, GSK’s dry powder inhaler. On Dec. 1, 2015, Propeller, based in Madison, Wisconsin, and GlaxoSmithKline, headquartered in London, entered into a research and development agreement…
For COPD Awareness Month this November, PMD Healthcare has just announced that it will be participating by having every member of the PMD team wear orange pins stating ‘ask me about COPD’, to heighten awareness for chronic obstructive pulmonary disease (COPD). According to Richard J. Martin, MD,…
The Aerobika device, developed by Monaghan Medical Corporation (MMC), is effective in reducing drug use and costs for patients with chronic obstructive pulmonary disease (COPD), according to a presentation at the recent American College of Chest Physicians (CHEST) annual meeting in Los Angeles. The Aerobika Oscillating Positive Expiratory Pressure (OPEP),…
The American College of Chest Physicians (CHEST) and Sunovion presented their new joint initiative called Delivery Makes a Difference at the CHEST 2016 Annual Meeting Oct. 22-26 in Los Angeles. Delivery Makes a Difference aims to increase awareness about the importance of drug delivery systems for diseases such as chronic obstructive pulmonary…
Theravance Biopharma and Mylan recently reported positive Phase 3 trial data on the effectiveness of the drug revefenacin (TD-4208) for the treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is an investigational long-acting muscarinic antagonist (LAMA) and the first once-daily nebulized bronchodilator in development to treat COPD. The drug will be…
Boehringer Ingelheim Pharmaceuticals and Ashfield Healthcare have launched a new and free patient support program. Called ‘STIOLTO Promise,’ the no-cost offer provides 30 days of medicine, resources, and at-home counseling via respiratory specialists for patients with chronic obstructive pulmonary disease (COPD) who are prescribed STIOLTO RESPIMAT. STIOLTO RESPIMAT was approved in May 2015 for…
ResApp Health, an Australian company developing digital healthcare solutions for respiratory conditions, recently reported additional preliminary positive results of its adult clinical trial assessing the company’s app for the diagnosis of different lung diseases, including chronic obstructive pulmonary fibrosis (COPD). According to a ResApp press release, the results showed that the…
A new research study suggests that high indoor temperatures could worsen the symptoms of chronic obstructive pulmonary disease (COPD), particularly in homes with high levels of air pollutants. Johns Hopkins University researchers conducted a longitudinal study including 69 patients with moderate-to-severe COPD during the hottest days of the year. The results of…
Researchers at Canada’s University of British Columbia (UBC) determined that despite a decline in smoking rates, there will be an epidemic of chronic obstructive pulmonary disease (COPD) over the next two decades, with the potential to overwhelm healthcare systems. The report with the predictions was published in the American Journal of…
The benefits of physical activity are widely accepted by scientists and doctors today, with effects observed in weight control, as well as mood and mental health. Now research is showing that increased physical activity among patients with chronic obstructive pulmonary disease (COPD) reduces their risk of anxiety and depression. Results from…
Get regular updates to your inbox.